Professor & patients' paper on the solvable biological challenge of ME/CFS: reader-friendly version
Simon McGrath provides a patient-friendly version of a peer-reviewed paper which highlights some of the most promising biomedical research on ME/CFS ...
Discuss the article on the Forums.

Grant to Hemispherx for Ampligen and Alferon

Discussion in 'XMRV Research and Replication Studies' started by Rita, Nov 14, 2010.

  1. Rita

    Rita Senior Member

    Nov. 10, 2010, 8:00 a.m. EST
    Hemispherx Biopharma Receives Therapeutic Discovery Project Grant From
    U.S. Department of Treasury
    Covers Therapeutic Applications of Two Technology Platforms

    PHILADELPHIA, Nov 10, 2010 (GlobeNewswire via COMTEX) -- Hemispherx
    Biopharma, Inc. /quotes/comstock/14*!heb/quotes/nls/heb (HEB 0.50,
    -.00, -0.44%) announced today grant awards totaling $488,958 from the
    U.S. Department of Treasury in support of its Ampligen(R) and
    Alferon(R) development programs. These awards were approved by the
    Internal Revenue Service (IRS), in conjunction with the Department of
    Heath and Human Services (DHHS), under the Qualifying Therapeutic
    Discovery Project Program, established under the Patient Protection
    and Affordable Care Act of 2010 for projects that showed significant
    potential to produce new and cost-saving therapies, support jobs and
    increase U.S. competitiveness. The amounts granted for these two
    Hemispherx projects were for the maximum per-project amount set by the
    IRS based on the limited amount of funds allocated for the program.

    The Hemispherx Alferon(R) program grant application was based on the
    potential to show Alferon N Injection(R), an FDA-approved treatment
    for refractory HPV, and Alferon(R) LDO (low dose oral), an
    experimental formulation, to be an efficacious and inexpensive
    preventative or treatment for seasonal and pandemic flu.

    The Hemispherx Ampligen(R) grant application was based on the
    continuing development of Ampligen(R) (an experimental therapeutic
    with broad spectrum antiviral properties) in clinical programs in
    Chronic Fatigue Syndrome, (CFS) and as an adjuvant for seasonal /
    pandemic influenza vaccines and cancer immunotherapy.
  2. Cort

    Cort Phoenix Rising Founder

    That's interesting. I say what's good for Hemispherx is good for us, really, - so good!
  3. eric_s

    eric_s Senior Member

    Switzerland/Spain (Valencia)
    I like this too. Is that the first such grant for Ampligen? A sudden interest in Ampligen would seem like a very good sign then.
  4. Michael Dessin

    Michael Dessin Senior Member

    yea, I think that fabulouso!!
  5. mojoey

    mojoey Senior Member

    We talked about this on another thread. This is old news from 2009. Check this out:,00.html

    Add up the amounts of the grants awarded to hemispherx in 2009 and you get $488958 which is the amount they announced in the article.

    Seeing as hemispherx is the source of the PR release, is it then true that they lied or at least were being misleading by announcing old news as new news? In either case I wouldn't be at all surprised.
  6. Michael Dessin

    Michael Dessin Senior Member

    Hey Joey! Thanks for the info
  7. dannybex

    dannybex Senior Member

    They have a long history of doing exactly that. Unfortunately...

    I don't understand how they can let the CEO get away with these things, repeatedly. A great example of his doublespeak occurred last year on several occasions during the months leading up to the FDA's ruling:

    "Monday's statement was likely crafted by Hemispherx's lawyers as a way to help CEO Bill Carter wiggle out of public statements he made in May and June claiming the Ampligen application to the U.S. Food and Drug Administration to be complete. Carter insisted regulators weren't asking for any additional information on Ampligen.

    Carter's made these statements both before and immediately after the FDA approval decision date for Ampligen on May 25, which came and went without any word from the agency. We now know that Carter's statements were demonstrably false. The FDA application for Ampligen was not complete because several items were outstanding, the company now states. These included FDA requests for data on Ampligen's safety both in humans and animals. The FDA also required additional information about Ampligen's manufacturing."

  8. eric_s

    eric_s Senior Member

    Switzerland/Spain (Valencia)
    Are you sure?

    It says
    How could it be old grants if the program was established under a law of 2010?

    Either way, if there were grants in 2009 too, it does not indicate a shift in policy. Too bad. But at least they get some money, which should be a good thing.

    If they only were a bit more serious, as they seem to have something that's at least more helpful than most of the rest...

See more popular forum discussions.

Share This Page